Biogen
Biogen is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative therapies for serious and complex diseases. The company maintains a leading position in neurology, specialized immunology, and rare diseases, with a primary focus on conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Its value proposition centers on advancing a deep pipeline of biological and small molecule treatments through internal research and strategic external collaborations.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Neurology
primaryThe company's largest product category, focusing on treatments for Multiple Sclerosis (MS), Alzheimer's disease, and neuropsychiatry. This segment includes a broad portfolio of interferon and oral therapies for MS and co-developed treatments for neurodegenerative pathologies.
TECFIDERA, VUMERITY, TYSABRI, AVONEX, PLEGRIDY, LEQEMBI, ZURZUVAE
Specialty pharmacies, Wholesale distributors, Hospitals, Physicians
Rare Disease
majorFocuses on high-unmet-need genetic and neuromuscular disorders, including Spinal Muscular Atrophy (SMA), Friedreich’s Ataxia (FA), and Amyotrophic Lateral Sclerosis (ALS).
SPINRAZA, SKYCLARYS, QALSODY
Specialty distributors, Specialty pharmacies, Major medical centers
Anti-CD20 Therapeutic Programs
majorCollaborative programs involving therapies for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and multiple sclerosis.
RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, COLUMVI
Oncology centers, Hospitals, Wholesale distributors
Biosimilars
moderateA portfolio of advanced biologic medicines that are highly similar to originator therapies, targeting inflammatory conditions such as rheumatoid arthritis and Crohn’s disease.
BENEPALI, IMRALDI, FLIXABI
Government health authorities, Wholesale distributors, Hospitals
Segment Financials
AVONEX — Total Revenue
View metricTECFIDERA — Total Revenue
View metricTYSABRI — Total Revenue
View metricSKYCLARYS — Total Revenue
View metricSPINRAZA — Total Revenue
View metricSPINRAZA — Percentage of royalties as per collaboration
View metricIMRALDI — Total Revenue
View metricFLIXABI — Total Revenue
View metricBENEPALI — Total Revenue
View metricBusiness Overview
Competitive Position
A global leader in neuroscience and rare disease therapies with a significant portfolio of market-leading MS and SMA treatments.
Geographies
United States, European Union, China, Japan, Brazil
Customer Segments
Patients, Healthcare Providers, Government Payors, Private Insurers
Upstream Dependencies
Contract manufacturing organizations, Specialized raw material suppliers, Academic research institutions, Clinical research organizations
Downstream Customers
Pharmaceutical wholesalers, Specialty pharmacies, Government healthcare programs (Medicare/Medicaid), Private health insurers
Competitors & Partners
Competitors
Partners
Rogers Corporation
ROG
Collaboration partner for anti-CD20 therapies including RITUXAN and OCREVUS.
Ionis Pharmaceuticals
IONS
Collaboration for antisense therapeutics including SPINRAZA and QALSODY.
Samsung Bioepis
Joint venture/collaboration for the development and commercialization of biosimilars.
Supernus Pharmaceuticals
SUPN
Collaboration for the commercialization of ZURZUVAE.
Denali Therapeutics Inc.
DNLI
Co-development partner for LRRK2 inhibitor in Parkinson's disease.
Stoke Therapeutics, Inc.
STOK
Collaboration for zorevunersen in Dravet syndrome.
Royalty Pharma
RPRX
Funding arrangement for the development of litifilimab.
Subsidiaries
Alcyone Therapeutics
Acquired clinical-stage biotechnology company focused on CNS therapeutics and delivery platforms.
Biogen FAQ
Common questions about Biogen
Biogen is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative therapies for serious and complex diseases. The company maintains a leading position in neurology, specialized immunology, and rare diseases, with a primary focus on conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Its value proposition centers on advancing a deep pipeline of biological and small molecule treatments through internal research and strategic external collaborations.
Biogen (BIIB) has a market capitalization of $28.3B and trades on NASDAQ.
Biogen generated $9.9B in trailing twelve-month revenue with net income of $1.4B, representing a net margin of 14.3%. Gross margin stands at 75.5%, with free cash flow of $2.4B. These figures are based on the Q1 2026 filing.
Biogen's key competitors include Eli Lilly and Company, Royalty Pharma plc Class A Ordinary Shares, Bristol-Myers Squibb Co., and others. These companies compete in similar markets and product categories.
Biogen has approximately 7,570 employees.